

**SECTION 1 IDENTIFICATION OF THE MATERIAL AND SUPPLIER**

Product (material) name: Phoenix Xylazine 2% Injection  
Other names: None allocated  
Recommended use: An analgesic, sedative, muscle relaxant for use in horses, deer, cattle, dogs and cats.  
Supplier Details: Phoenix Pharm Distributors Ltd  
3C Whetu Place, Rosedale  
AUCKLAND 0632  
NEW ZEALAND  
Contact Person: Graeme Webb  
Telephone: +64 9 476 7391  
Facsimile: +64 9 479 5555  
Emergency telephone number: 0800 764 766 (0800 POISON) 24/7 for Poison Information Services  
111 for NZ emergency services

**SECTION 2 HAZARDS IDENTIFICATION**

Classification of Product:

This product is classified as a health hazard in accordance with the following classification criteria of the Globally Harmonized System of Classification and Labelling of Chemicals (GHS), Seventh Revised Edition.

Health hazards: Acute toxicity, oral  
Serious eye damage / eye irritation  
Skin corrosion / irritation

Acute toxicity, oral: Category 5  
GHS label elements, including precautionary statements:  
Pictogram: Not required  
Signal word: Warning  
Hazard statements: May be harmful if swallowed

Precautionary statements:  
Prevention: Keep out of reach of children  
Wear suitable protective clothing and gloves  
Do not eat drink or smoke when using this product  
Wash hands thoroughly after handling  
Response: If swallowed, call a Poisons Information Centre or doctor if you feel unwell  
Rinse mouth

Serious eye damage / eye irritation: Category 2  
GHS label elements, including precautionary statements:  
Pictogram:



Signal word: Warning  
Hazard statement: Causes serious eye irritation  
Precautionary statements:  
Prevention: Avoid contact with eyes. Wear safety glasses / goggles  
Wash hands thoroughly after handling  
Response: If in eyes rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
Get medical advice.

Skin irritant: Category 3  
GHS label elements, including precautionary statements:  
Pictogram: Not required  
Signal word: Warning  
Hazard statements: Causes mild skin irritation  
Precautionary statements:  
Prevention: Keep out of reach of children  
Wear suitable protective clothing and gloves  
Do not eat drink or smoke when using this product  
Wash hands thoroughly after handling  
Response: If on skin wash with plenty of soap and water  
If skin irritation occurs get medical advice/attention

### SECTION 3 COMPOSITION/INFORMATION ON INGREDIENTS

INGREDIENTS	Cas No.	Proportion (% w/v)
Xylazine Hydrochloride	23076-35-9	2.33
Chlorocresol	59-50-7	1
Water for Injection	7732-18-5	QS 100.00

### SECTION 4 FIRST AID MEASURES

**First Aid:**

If poisoning occurs, contact a doctor or Poisons Information Centre. Phone New Zealand 0800 764 766 (0800 POISON); Australia 13 11 26. If skin or hair contact occurs remove contaminated clothing and flush skin and hair with running water.

However, the following additional information is provided for assistance while implementing the recommended First Aid directions:

Swallowed: Follow general first aid instructions.  
Eye: If in eyes, hold eyes open and flood eyes with water for at least 15 minutes.  
Inhaled: Remove to fresh air, rest patient and seek medical advice if necessary.

First Aid Facilities: No specific first aid facilities required.

**Advice to Doctor:**

Treat symptomatically. The patient will usually recover over 1-2 days with supportive treatment. Yohimbine and 4-aminopyridine are xylazine antagonists used to reverse the effects of xylazine sedation in animals; however, they are not registered for use in humans.

### SECTION 5 FIRE FIGHTING MEASURES

Flammability: This product is not flammable.  
Suitable extinguishing media: Use media suitable for surrounding fire  
Hazards from combustion products: None known  
Special protective precautions and equipment for fire fighters: Use precautions and equipment suitable for the surrounding fire.

### SECTION 6 ACCIDENTAL RELEASE MEASURES

**Emergency procedures:**

Contain spill for salvage or absorb in inert absorbent material. Avoid contact with skin and eyes during clean up. Wear respirator, goggles and protective gloves for large spillages. Ventilate area.

Methods and materials for containment and clean up:

Absorb onto paper towel, hydrated lime, soil or sand, depending on quantity involved. Dispose of contaminated absorbent material in accordance with local, state and federal regulations. Wash contaminated area with copious volumes of water.

### SECTION 7 HANDLING AND STORAGE

Precautions for safe handling:

Avoid contact with eyes, skin and clothing. Avoid generating or breathing product aerosol. Wash after handling.

Conditions for safe storage, including any incompatibilities:

Store below 25°C (Room Temperature). Protect from light.

Store away from food, drink or feedstuffs.

### SECTION 8 EXPOSURE CONTROLS/PERSONAL PROTECTION

National exposure standards:	None allocated.
Biological limit values:	None allocated.
Engineering controls:	Ventilation not considered necessary during normal usage.
Personal protective equipment:	None considered necessary during normal usage.

### SECTION 9 PHYSICAL AND CHEMICAL PROPERTIES

Appearance:	Clear, odourless solution
Boiling Point [°C]:	Not determined
Vapour Pressure [mm of Hg at 20°C]:	Not determined
pH:	4.5 - 6.0
Specific Gravity:	1.004
Flash Point [°C]:	Not determined
Flammability Limits [%]:	Not determined
Autoignition temperature [°C]:	Not determined

### SECTION 10 STABILITY AND REACTIVITY

Chemical stability:	Stable under normal usage conditions
Conditions to avoid:	None known
Incompatible materials:	Acids, alkalis
Hazardous decomposition products:	Oxides of carbon and nitrogen are formed under thermal decomposition.
Hazardous reactions:	Hazardous polymerisation has not been reported

### SECTION 11 TOXICOLOGICAL INFORMATION

Routes of Exposure:

Phoenix Xylazine Injection 2% is an injectable product contained in a labelled 50ml multidose amber glass vial sealed with a rubber stopper and aluminium cap, packaged in outer labelled carton. It is considered that the most likely routes of exposure will be eye and skin contact and accidental injection.

Signs and symptoms of exposure

Signs of toxicity include reduced heart rate, irregular heartbeat, difficulty in breathing, cyanosis, (turning blue), drowsiness, slurred speech, incoordination and unconsciousness.

Summary of Toxicology

Xylazine is an alpha-2 adrenergic, non-narcotic sedative. It produces sedation via stimulation of CNS presynaptic alpha-2 adrenergic receptors. Xylazine may produce a significant reduction in blood pressure, and varying degrees of sedation progressing through to coma, depending on the dosage administered.

Acute Toxicity:

LD<sub>50</sub> Oral  
Rat: 130 mg/kg  
Mouse: 240 mg/kg  
LD<sub>50</sub> Intramuscular  
Dog: 47 mg/kg  
Horse: 60-70 mg/kg  
LD<sub>50</sub> Subcutaneous  
Mouse: 121 mg/kg  
Cat: 105 mg/kg

No chronic health effects reported.

## SECTION 12 ECOLOGICAL INFORMATION

No ecological information available

## SECTION 13 DISPOSAL CONSIDERATIONS

Disposal methods and containers:  
Dispose of empty container by wrapping with paper and putting in garbage.

Special precautions for landfill or incineration:  
None known. Contact local government authority before disposing of this material in municipal landfill.

## SECTION 14 TRANSPORT INFORMATION

Not classified as dangerous goods under the United Nations Recommendations on the Transport of Dangerous Goods or the Australian Code for the Transport of Dangerous Goods by Road or Rail.

## SECTION 15 REGULATORY INFORMATION

New Zealand  
Phoenix Xylazine 2% Injection is registered as a veterinary medicine under the Agricultural Compounds and Veterinary Medicines (ACVM) Act 1997 and Regulations.

Registration Number: **A006540**  
For conditions of registration see [www.mpi.govt.nz/](http://www.mpi.govt.nz/)

HSNO approval number: HSR002335  
Hazard classifications: 6.1E (All), 6.3B, 6.6B, 6.7B, 6.9B (All)  
For full listing of controls see [www.epa.govt.nz/](http://www.epa.govt.nz/)

Australia  
Xylazine is a Schedule 4 medicine (prescription only medicine) under the Australian Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP).

Xylazine has been identified as not requiring assessment under the Australian National Industrial Chemicals Notification and Assessment Scheme as it is controlled under legislation specific to human and animal health.

## SECTION 16 OTHER INFORMATION

SDS version:	2
Date of Revision:	May 2018
Update of sections:	Update to GHS

CONTACT POINT                      Graeme Webb  
Telephone:                              +64 9 476 7391  
Facsimile:                                +64 9 479 5555

**References:**

1. FAISD Handbook, Handbook of First Aid Instructions, Safety Directions, Warning Statements, and General Safety Precautions for, Agricultural and Veterinary Chemicals, (as updated), <https://apvma.gov.au/node/26586>
2. Model Code of Practice: Preparation of safety data sheets for hazardous chemicals, <https://www.safeworkaustralia.gov.au/doc/model-code-practice-preparation-safety-data-sheets-hazardous-chemicals>
3. AICS (Australian Inventory of Chemical Substances), Safework Australia, <https://www.nicnas.gov.au/forms/Australian-Inventory-of-Industrial-Substances>
4. APVMA Guidelines for registration of veterinary chemical products - <https://apvma.gov.au/node/6>
5. ADI [Acceptable Daily Intake] List, Commonwealth Department of Health & Aged Care, TGA, (as updated)
6. The Australian Code for the Transport of Dangerous Goods by Road and Rail (ADG Code) 7<sup>th</sup> Edition
7. The Poisons Standard (as updated), National Drugs and Poisons Schedule Committee, <https://www.tga.gov.au/publication/poisons-standard-susmp>
8. Hazardous Substances Information System, Safework Australia (as updated), <http://hcis.safeworkaustralia.gov.au/>
9. Globally Harmonized System of Classification and Labelling of Chemicals (GHS), Seventh Revised Edition, United Nations, New York and Geneva, 2017, [https://www.unece.org/trans/danger/publi/ghs/ghs\\_rev07/07files\\_e.html](https://www.unece.org/trans/danger/publi/ghs/ghs_rev07/07files_e.html)
10. NIOSH Pocket Guide to Chemical Hazards
11. Chemical Classification and Information Database (CCID) (as updated), New Zealand Environmental Protection Authority: <https://www.epa.govt.nz/database-search/chemical-classification-and-information-database-ccid/>
12. European Chemical Agency (ECHA), Information on Chemicals, <https://echa.europa.eu/information-on-chemicals>

DISCLAIMER: All information given in this data sheet and by the company's technical staff is compiled from the best information currently available to the company. The company accepts no responsibility whatsoever for its accuracy or for any results which may be obtained by customers. Any customer who relies upon any advice or information given in this data sheet by the company or by its technical staff does so entirely at its own risk, and the company will not be liable for any loss or damage thereby suffered notwithstanding any want of care on the part of the company or its staff in compiling or giving the advice or information.